GH Insider Trading

Insider Ownership Percentage: 5.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $198,440.40

Guardant Health Insider Trading History Chart

This chart shows the insider buying and selling history at Guardant Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$5.20ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Guardant Health Share Price & Price History

Current Price: $49.53
Price Change: Price Increase of +1.54 (3.21%)
As of 04/29/2025 05:00 PM ET

This chart shows the closing price history over time for GH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$47.99Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Guardant Health (NASDAQ:GH)

92.60% of Guardant Health stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$34Mbought$6.78MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4B-$2B$0$2B$4BTotal InflowsTotal Outflows
Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Read More on Guardant Health

Today's Range

Now: $49.53
Low: $47.47
High: $50.24

50 Day Range

MA: $43.35
Low: $35.84
High: $48.30

52 Week Range

Now: $49.53
Low: $17.52
High: $50.89

Volume

2,256,189 shs

Average Volume

2,144,459 shs

Market Capitalization

$6.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Who are the company insiders with the largest holdings of Guardant Health?

Guardant Health's top insider investors include:
  1. Kumud Kalia (Insider)
  2. Meghan V Joyce (Director)
  3. Musa Tariq (Director)
Learn More about top insider investors at Guardant Health.

Who are the major institutional investors of Guardant Health?

Guardant Health's top institutional shareholders include:
  1. Sumitomo Mitsui Trust Group Inc. — 1.10%
  2. Principal Financial Group Inc. — 0.40%
  3. Rhumbline Advisers — 0.14%
  4. Sicart Associates LLC — 0.11%
  5. Penserra Capital Management LLC — 0.04%
  6. Handelsbanken Fonder AB — 0.03%
Learn More about top institutional investors of Guardant Health stock.

Which institutional investors are selling Guardant Health stock?

During the previous quarter, GH stock was sold by these institutional investors:
  1. Sumitomo Mitsui Trust Group Inc.
  2. D.A. Davidson & CO.
  3. Cambridge Investment Research Advisors Inc.
  4. Exchange Traded Concepts LLC
  5. Sicart Associates LLC
  6. Fiduciary Alliance LLC
During the last year, company insiders that have sold Guardant Health company stock include:
  1. Kumud Kalia (Insider)
  2. Meghan V Joyce (Director)
Learn More investors selling Guardant Health stock.

Which institutional investors are buying Guardant Health stock?

Within the previous quarter, GH stock was purchased by institutional investors including:
  1. Principal Financial Group Inc.
  2. Penserra Capital Management LLC
  3. Lisanti Capital Growth LLC
  4. Teacher Retirement System of Texas
  5. GAMMA Investing LLC
  6. Envestnet Asset Management Inc.
  7. MRA Advisory Group
  8. Oppenheimer & Co. Inc.